top of page
Watch: Inside the KappaMab manufacturing process
14 June 2023
We’re pleased to announce that our third batch of our lead candidate, KappaMab, has arrived in Australia.
The drug is being stored at Cryosite and is ready to use in patients in the next planned clinical trial, which is a Phase II dose optimisation and combination study with Pomalidomide and dexamethasone.
This video takes you inside the state-of-the-art KappaMab manufacture process, which is subject to meticulous quality control that gives an incredibly low rejection rate of less than 1%.
bottom of page